Back to SGEN Stock Lookup

SGEN Related FDA

Jun 10, 2013 09:06 AM Seattle Genetics (SGEN) Initiates ADCETRIS Phase 1/2

Mar 18, 2013 09:08 AM Seattle Genetics (SGEN) Submits sBLA to FDA for Broader ADCETRIS Usage

Feb 1, 2013 02:07 PM Seattle Genetics' (SGEN) ADCETRIS Approved by Health Canada

Jan 24, 2013 09:02 AM Seattle Genetics (SGEN), Millennium Initiate ADCETRIS Phase III

Dec 11, 2012 07:06 AM Seattle Genetics (SGEN) Updates on Select ADC Programs by Roche's (RHHBY) Genentech

Dec 10, 2012 10:03 AM Seattle Genetics (SGEN) Updates on ADCETRIS in Relapsed HL

Nov 20, 2012 11:04 AM Seattle Genetics (SGEN) granted FDA orphan drug status for Mycois Fungoides

Oct 31, 2012 07:09 AM Seattle Genetics (SGEN) AADCETRIS® Receives EC Conditional Marketing Authorization

Oct 23, 2012 09:05 AM Seattle Genetics (SGEN) Expands ADC Collaboration w/ Abbott (ABT); Will Get $25M Upfront

Oct 17, 2012 09:09 AM Seattle Genetics (SGEN) Initiates ADCETRIS Phase II in New HL Patents Over 60

Oct 1, 2012 06:51 AM Millennium, Seattle Gen (SGEN) Updates on Sequential Therapy with Brentuximab Vedotin in Newly Diagnosed Patients with Systemic Anaplastic Large Cell Lymphoma

Sep 25, 2012 09:11 AM Seattle Genetics (SGEN) and Millennium Complete Enrollment for Phase III AETHERA Trial of ADCETRIS

Jul 20, 2012 10:46 AM Seattle Genetics (SGEN) Says Takeda Gets Positive ADCETRIS Recommendation from CHMP

Jun 14, 2012 07:06 AM Seattle Genetics (SGEN) Offers Updated Survival Data for Adcetris Trial, Says Median Overall Survival at 24 Months 65%

Jun 4, 2012 06:56 AM Seattle Genetics (SGEN) to Present Data from Several ADCETRIS Trials at ASCO

May 10, 2012 10:05 AM Seattle Genetics (SGEN) Updates on ADCETRIS Interim Phase II Data

Jan 13, 2012 06:47 AM Seattle Genetics (SGEN) Updates on Prescribing Info for ADCETRIS; Highlights PML Warning

Dec 12, 2011 01:03 PM Seattle Genetics (SGEN) Says ADCETRIS Has Clinically Meaningful Response, Safety Profile

Oct 25, 2011 09:04 AM Seattle Genetics (SGEN) Initiates ADCETRIS Phase II

Sep 26, 2011 07:05 AM Takeda, Seattle Genetics (SGEN) Applys for ADCETRIS MAA in Europe

Aug 23, 2011 09:39 AM Seattle Genetics (SGEN) Initiates Phase II Clinical Trial of ADCETRIS in CD30-Positive Non-Hodgkin Lymphoma

Aug 19, 2011 01:54 PM Seattle Genetics (SGEN) on the move as FDA has approved its lymphoma drug

Jul 15, 2011 10:03 AM Jefferies Boosts PT on Seattle Genetics (SGEN) Following FDA Panel Vote; Is Buyer on Weakness

Jul 14, 2011 05:05 PM Seattle Genetics (SGEN) Resumes Trading; Shares Down 9%

Jul 14, 2011 04:43 PM Seattle Genetics (SGEN) Set to Resume Trading at 5:05PM ET

Jul 14, 2011 04:35 PM Seattle Genetics (SGEN) Announces FDA Advisory Committee in Favor of Accelerated Approval of ADCETRIS

Jul 14, 2011 11:32 AM FDA Advisory Panel Votes 10-0 for Fast Approval of Seattle Genetics' Hodgkin Drug

Jul 12, 2011 03:33 PM Needham & Company maintains a 'Buy' on Seattle Genetics (SGEN); FDA Briefing Documents for the BLAs of ADCETRIS

Jul 12, 2011 08:10 AM Seattle Genetics (SGEN) FDA Briefing Documents Posted

Jun 27, 2011 07:23 AM Seattle Genetics (SGEN) to Receive Multi-Million Milestone Under ADCETRISTM Collaboration

Jun 16, 2011 09:02 AM Seattle Genetics (SGEN) Sets Date with FDA to Review Biologics License Applications for Brentuximab Vedotin

Jun 6, 2011 07:25 AM Jefferies Reiterates Bullish Stance On Seattle Genetics (SGEN) Related To Eventual Adcentris Label

May 27, 2011 09:06 AM Millennium, Seattle Gen (SGEN) to Present Brentuximab Vedotin Data

May 19, 2011 08:24 AM Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO

May 2, 2011 06:50 AM U.S. FDA Accepts Seattle Genetics' (SGEN) Brentuximab Vedotin BLA

Apr 6, 2011 08:48 AM Seattle Genetics (SGEN) Updates on SGN-35 in Hodgkin Lymphoma Patients

Mar 22, 2011 09:02 AM Seattle Genetics (SGEN), Abbott (ABT) Enter ADC Technology Collaboration

Mar 1, 2011 08:41 AM Seattle Genetics (SGEN), Millennium Initiate SGN-35 Phase I

Feb 28, 2011 06:52 AM Seattle Genetics (SGEN) Submits BLA for Brentuximab Vedotin to U.S. FDA

Dec 7, 2010 07:40 AM Seattle Genetics (SGEN) and Millennium Announce Positive Phase II SGN-35 Data in Patients with Relapsed ALCL

Dec 6, 2010 09:20 AM Seattle Genetics (SGEN) and Millennium Announce Positive Results of SGN-35 on Patients with HL

Dec 6, 2010 09:02 AM Ariad (ARIA) May Have Been Best at ASH Meeting

Oct 29, 2010 07:43 AM Compugen (CGEN) Signs Collaboration Agreement with Seattle Genetics (SGEN)

Oct 11, 2010 07:11 AM Seattle Genetics and Millennium Anounce Positive Results in SGN-35 Phase II

Oct 11, 2010 07:10 AM Seattle Genetics (SGEN) Announces Data from SGN-75 Phase I

Sep 27, 2010 11:13 AM Needham & Company Lifts Target On Seattle Genetics (SGEN) Following Positive Data

Sep 27, 2010 07:12 AM Seattle Genetics (SGEN) and Takeda Announce Positive Results in SGN-35 Trial

Sep 14, 2010 08:27 AM Genmab A/S and Seattle Genetics (SGEN) Announces ADC Research Collaboration Agreement

Sep 13, 2010 06:52 AM Seattle Genetics (SGEN) Said Lintuzumab Did Not Meet Primary Endpoint

Sep 13, 2010 06:51 AM Seattle Genetics (SGEN) Reports Lintuzumab Phase IIb Did Not Meet Primary Endpoint; To Discontinue Development

Back to SGEN Stock Lookup